The Life Sciences team advised Moderna, Inc. (Nasdaq:MRNA) on its strategic collaboration with Generation Bio Co. (Nasdaq:GBIO) to combine Moderna's biological and technical expertise with core technologies of Generation Bio's non-viral genetic medicine platform. The collaboration aims to expand the application of each company's platform by developing novel nucleic acid therapeutics, including those capable of reaching immune cells, to accelerate their respective pipelines of non-viral genetic medicines.
Generation Bio will receive a $40 million upfront cash payment and a $36 million equity investment issued at a premium over recent share prices. Moderna will fund all collaboration work, including a research pre-payment.
In over 10 years since its inception, Moderna has transformed from a research-stage company advancing programs in the field of messenger RNA (mRNA), to an enterprise with a diverse clinical portfolio of vaccines and therapeutics across seven modalities, a broad intellectual property portfolio in areas including mRNA and lipid nanoparticle formulation, and an integrated manufacturing plant that allows for rapid clinical and commercial production at scale.
Generation Bio is innovating genetic medicines to provide durable, redosable treatments for people living with rare and prevalent diseases.
The Goodwin team was led by Can Cui, Kingsley Taft, Gregg Katz, Jim Matarese, Stuart Cable, Matthew Rosencranz, Megan Riley, Nathan Needle and Sarah Mackin, with invaluable assistance from Arman Oruc and Kevin Walsh.
For more details, read the press release and articles in Fierce Biotech and Reuters.